Bis-organometallic 2-amino-3-hydroxy-2-methylpropanenitrile derivatives for use as anthelmintics

ABSTRACT

The invention comprises a compound characterized by a general formula (1). 
     
       
         
         
             
             
         
       
     
     wherein X is a group described by a general formula wherein
         is with l being 0 or 1,   is a —alkyl with p being or   is a —alkyl with q being or 4, and
 
wherein Z is a group described by a general formula wherein
   with l being 0 or 1,   K r  is a —alkyl with r being 0, 1, 2, 3 or 4,   K t  is a —alkyl with t being 0, 1, 2, 3 or 4,   wherein each OM is an organometallic compound independently selected from each other from the group of an unsubstituted or substituted metal sandwich compound, an unsubstituted or substituted half metal sandwich compound or a metal carbonyl compound and their use.

FIELD OF THE INVENTION

The present invention relates to bis-organometallic 2-amino-3-hydroxy-2-methylpropanenitrile derivatives and their use as anthelmintics.

BACKGROUND OF THE INVENTION

Parasites cause significant economic losses to agriculture worldwide due to poor productivity, limited growth rates and death. According to some estimates, the financial damage caused by parasites to the livestock industry is in the order of tens of billions of dollars per annum. Decreased productivity influences not only the livestock industry but also substantially affects global food production, Moreover, in spite of fie anthelmintic drugs discovered and marketed in the last decades, problems of parasitic worms persist and multi-drug resistance to most classes of anthelmintics is widespread. The development of new classes of anthelmintics Is a major priority. Any anthelmintic developed for parasites of livestock would also have application to parasites of humans and other animals, including companion animals, such as dogs, cats and equids. One sixth of the human population in earth is affected chronically by at least one parasitic helminth, and the socioeconomic burden (in DALYs) is greater than that of cancer and diabetes. Some helminths, such as Schistosoma haematobium, Opistorchis viverrim and Clonorchis sinensis induce malignant cancers in humans.

Recently, a new class of synthetic anthelmintics referred to as Amino-Acetonitrile Derivatives (AADs, see has been commercially developed under the trade name Zolvix® (also known as monepantel) for the treatment of infected sheep.

Monepantel (AAD 1566)

The precise mode of action of monepantel is not yet elucidated, although an interaction of AADs with a specific acetylcholine receptor subunit has been proposed. This target is only present in nematodes but not in mammals, making it relevant for the development of a new class of anthelmintic drugs. Of high importance, a mutant of Haemonchus contortus with a reduced sensitivity to monepantel was recently identified using a novel in vitro selection procedure (L, Rufener, R, Baur, R. Kaminsky, P. Maeser and E. Sigel, Mol. Pharmacol,, 2010, 78, 895-902), indicating that resistance will develop in gastrointestinal nematodes of livestock. This observation has been noticed for ail current anthelmintics on the market, in light of the above referenced state of the art, the objective of the present invention is to provide novel compounds to control parasites of human beings and livestock.

This objective is attained by the subject-matter of the independent claims.

SUMMARY OF THE INVENTION

According to a first aspect of the invention provided herein are organometallic compounds characterized by a general formula (1),

wherein X is a group described by a general formula wherein

-   -   is—with I being 0 or 1,     -   is a —alkyl with p being 0, 1, 2, 3 or 4,     -   is a —alkyl with q being 0,1, 2, 3 or 4, and         wherein Z is a group described by a general formula wherein     -   or with i being 0 or 1,     -   is a —alkyl with r being 0,1, 2, 3 or 4,     -   is a —alkyl with t being 0,1,2, 3 or 4,         wherein OM is an organometallic compound independently selected         from the group of an substituted or substituted metal sandwich         compound, an unsubstituted or substituted half metal sandwich         compound or a metai carbonyl compound,

The term “substituted” refers to the addition of a substituent group to a parent compound.

“Substituent groups” can be protected or unprotected and can be added to one available site or to many available sites in a parent compound. Substituent groups may also be further substituted with other substituent groups and may be attached directly or by a linking group such as an alkyl, an amide or hydrocarbyl group to a parent compound, “Substituent groups” amenable herein include, without limitation, halogen, oxygen, nitrogen, sulphur, hydroxyl, alkyl, alkenyl, alkynyl, acyl carboxyl aliphatic groups, alicyclic groups, alkoxy, substituted oxy aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino imino amido or hydrazine derivates tetrazole azido nitro cyano isocyano cyanato isocyanato thiocyanato isothiocyanato or thiol sulfinyl. sulfonyl sulfonamidyl or and fluorinated compounds. Wherein each and is, independently, H or a further substituent group with a preferred list including without limitation, H, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl.

As used herein the term “alkyl,” refers to a saturated straight or branched hydrocarbon moiety containing up to 10, particularly up to 4 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl and the like. Alkyl groups typically include from 1 to about 10 carbon atoms (alkyl), particularly with from 1 to about 4 carbon atoms (alkyl). The term “cycloalkyl” refers to an interconnected alkyl group forming a ring structure. Alkyl or cycloalkyl groups as used herein may optionally include further substituent groups. Examples for a substituted alkyl group (e.g. a substituted or a substituted —may be—, thus, comprising additional fluorides as substituents.

As used herein the term “alkenyl,” refers to a straight or branched hydrocarbon chain moiety containing up to 10 carbon atoms and having at least one carbon-carbon double bond. Examples of alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 2 to about 10 carbon atoms, more typically from 2 to about 4 carbon atoms. Alkenyl groups as used herein may optionally include further substituent groups.

As used herein the term “alkynyl,” refers to a straight or branched hydrocarbon moiety containing up to 10 carbon atoms and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, and the like. Alkynyl groups typically include from 2 to about 10 carbon atoms, more typically from 2 to about 4 carbon atoms. Alkynyl groups as used herein may optionally include further substituent groups.

As used herein the term “aryl” refers to a hydrocarbon with alternating double and single bonds between the carbon atoms forming a ring structure (in the following an “aromatic hydrocarbon”). The term “heteroaryl” refers to aryl compounds in which at least one carbon atom is replaced with an oxygen, a nitrogen or a sulphur atom. The aromatic hydrocarbon may be neutral or charged. Examples of aryl or hetero aryl groups are benzene, pyridine, pyrrole or cyclopenta-1,3-diene-anion. Aryl or hetero aryl groups as used herein may optionally include further substituent groups.

As used herein the term “organometallic compound” refers to a compound comprising at least one metal, in particular at least one transition metal (a metal selected from the group 3 to group 12 metals of the periodic table), as well as at least one metal-carbon bond.

As used herein the term “metal sandwich compound” refers to a compound comprising a metal, in particular a transition metal, bound to two aryl or heteroaryl ligands (in the following “sandwich ligands”) by a haptic covalent bound. It may comprise a cationic metal sandwich complex, e.g. cobaltocenium with a suitable counter anion such as iodide, chloride, bromide, fluoride, triflate, tetraborofluoride, hexafluorophosphate. The aryl or heteroaryl ligands may be unsubstituted or substituted.

As used herein the term “half metal sandwich compound” refers to a compound comprising a metal, in particular a transition metal, bound to just one aryl or heteroaryl ligand (sandwich ligand). The other ligand may comprise—without being limited to—alkyl, allyl, in particular CO.

As used herein the term “metal carbonyl compound” refers to a coordination complex of at least one transition metal with a carbon monoxide (CO) ligand. It may comprise a neutral, anionic or cationic complex. The carbon monoxide ligand may be bond terminally to a single metal atom or may be bridging to two or more metal atoms. The complex may be homoeleptic (containing only carbon monoxide ligands) or heteroeleptic.

As used herein the term “metallocene” refers to a metal sandwich compound comprising an aryl or heteroaryl five ring ligand (in the following “cp-ligand” or “hetero cp-ligand”).

In some embodiments, one organometallic compound may be attached directly to the moiety of the parent compound (e.g. with l, q and p being 0). In some embodiments, one organometallic compound may be connected by a to alkyl to themoiety of the parent compound (e.g. with l and q being 0 and p being an integer of 1 to 4, in particular p being 1. In some embodiments, one organometallic compound may be connected to the moiety of the parent compound by a group, in particular by a —group, with l being 1, q being 0 and p being 0 (e.g. In some embodiments, one organometallic compound may be connected to the moiety of the parent compound by a group, in particular by a group, with l being 1, q being 0 and p being an integer of 1 to 4, in particular p being 1 (e.g. In some embodiments, one organometallic compound may be connected to the—moiety of the parent compound by a group, in particular by a group, with l being 1, p being 0 and q being an integer of 1 to 4, in particular q being 1 (e.g. In some embodiments, the organometallic compound may be attached directly to the moiety of the parent compound (e.g. with i, r and t being 0. In some embodiments, the organometallic compound may be connected by -alkyl to the moiety of the parent compound with i and t being 0 and r being an integer of 1 to 4, in particular r being 1 (e.g. In some embodiments, the organometailic compound may be connected to the —moiety of the parent compound by a alkyl-alkyl-alkyl-alkylalkyl—or -alkyl—group, with with i being 1, r being an integer of 1 to 4, in particular r being 1, and t being 0 (e.g.

-   -   or In some embodiments, the organometallic compound may be         connected to the moiety of the parent compound by a alkylalkyl         or alkylalkyl group, with i being 1, r and t being an integer of         1 to 4 (e.g.

In some embodiments, i of and t of are 0.

In some embodiments, l of

In some embodiments) with l being 1. In some embodiments, is with l being 1,

In some embodiments, l, wherein q of and p of are 0.

In some embodiments with l being 1, wherein q of and p of are 0. In some embodiments with l being 1, wherein q of and p of are 0.

In some embodiments, with l being 1, q of is 0 and is -alkyl In some embodiments, is—with l being 1, q of is 0 and is -alkyl.

In some embodiments, i of is 0, q of is 0 and is alkyl. In some embodiments, l of is 0, q of is 0 and is.

In some embodiments, with l being 1, p of is 0 and is -alkyl in some embodiments, is—with l being 1, p of K_(p) is 0 and is -alkyl.

In some embodiments, with l being 1, is -alkyl and is -alkyl or

C₂-alkyl. In some embodiments, with l being 1, is alkyl and is alkyl or -alkyl.

In some embodiments, i of, r of and t of are 0 and

-   -   l of F_(l) is 0.     -   ) with l being 1,     -   with l being 1,     -   l of is 0, wherein q of and p of are 0,     -   with l being 1, wherein q of and p of are 0,     -   with l being 1, wherein of and of are 0,     -   with l being 1, q of is 0 and is alkyl,     -   with l being 1, q of is 0 and is -alkyl,     -   with l being 1, is -alkyl and is -alkyl or -alkyl,     -   is with l being 1, is -alkyl and is -alkyl or -alky,     -   with l being 1, p of is 0 and is -alkyl,     -   with l being 1, p of is 0 and is -alkyl.

In some embodiments, at least one OM is a metal sandwich complex, wherein each of the two sandwich ligands is selected independently from a five-membered or six-membered aryl group or a five-membered or six-membered heteroaryl group. In some embodiments, at least one OM is a metal sandwich complex, wherein both sandwich ligands are the same and are selected from a five-membered or six-membered aryl group or a five-membered or six-membered heteroaryl group. In some embodiments, at least one OM is a metal sandwich complex, wherein at least one of the two ligands is selected from a five-membered or six-membered aryl group, wherein the other is selected from a five-membered or six-membered heteroaryl group. In some embodiments, at least one OM is a substituted or unsubstituted metallocene, wherein each of two ligands is selected independently from a five-membered aryl group (cp-ligand) or a five-membered heteroaryl group (hetero cp-ligand). The metal sandwich complex may be connected to the parent molecule by any atom of one of the two sandwich ligands Furthermore or additionally, it may comprise a cationic metal sandwich complex, e.g. cobaltocenium with a suitable counter anion such as iodide, chloride bromide, fluoride, triflate, tetrafluoroborate or hexafluorophosphate.

In some embodiments, both OM are the same.

In some embodiments, OM is a metal sandwich complex of the general formula (2a),

wherein M is a metal selected from the group, and

-   -   Y is or M, and     -   z of is 0,1, 2, 3 or 4, and y of is 0,1, 2, 3, 4 or 5 and     -   each and each are independently from any other and selected from     -   an unsubstituted or substituted alkyl, an unsubstituted or         substituted alkenyl, an     -   unsubstituted or substituted alkynyl, an unsubstituted or         substituted cycloalkyl, an     -   unsubstituted or substituted alkoxy, an unsubstituted or         substituted cycloalkoxy,     -   an unsubstituted or substituted -aryl,     -   an unsubstituted or substituted 5- to 10-membered heteroaryl,         wherein 1 to 4 ring atoms are independently selected from         nitrogen, oxygen or sulfur,     -   an unsubstituted or substituted 5- to 10-membered         heteroalicyclic ring, wherein 1 to 3 ring atoms are         independently selected from nitrogen, oxygen or sulfur,     -   wherein         -   and are independently selected from the group consisting of             hydrogen, unsubstituted or substituted alkyl, in particular             a substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of is 0, 1 , 2, 3 or 4, and y of is 0, 1 , 2, 3, 4 or 5, and each and each are independently from any other and R^(u) selected from or, wherein and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of is 0, 1 , 2, 3 or 4, and y of is 0, 1 , 2, 3, 4 or 5, and each and each R^(U) are independently from any other and selected from in particular from —or —wherein R³ and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, M of the general formula 2a is. In some embodiments, M of the general formula 2a is. In some embodiments, M of the general formula 2a is Fe.

In some embodiments, Y is

In some embodiments, M of the general formula 2a is Fe and Y is C.

In some embodiments, Y is, and z of is 0, 1 , 2, 3 or 4, y of is 0, 1 , 2, 3, 4 or 5, and each and each are independently from any other and selected from —, wherein and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of is 1 and y of is 0 and is situated on the neighboring carbon atom of the cp-ligand with respect to the attachment position of the organometallic moiety (yielding a 1,2 substitution pattern on the cp-ligand).

In some embodiments, is, and z of is 0, 1, 2, 3 or 4, y of is 0, 1, 2, 3, 4 or 5, and each and each are independently from any other and selected from—,

-   -   wherein R³ and R⁴ are independently selected from the group         consisting of hydrogen, unsubstituted or substituted alkyl, and         alkyl substituted with alkoxy.

In some embodiments, M of the general formula 2a is a metal selected from the group of or, in particular is 1, y of is 1, and wherein and are selected independently from any other and from—more particularly from wherein R³ and R₄ are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, M of the general formula 2a is a metal selected from the group of or Mn, in particular M is or, more particularly is is or and z of is 1, and wherein is selected from—more particularly from—wherein and are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, M of the general formula 2a is a metal selected from the group of, or, in particular M is or, more particularly M is Fe, Y is C or N, and z of is 1, y of is 0, and wherein R^(u) is selected from—wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, Y is C, and z of is 0, 1,2,3 or 4, y of is 0; 1, 2, 3,4 or 5, and each R^(L) and each are independently from any other and selected from—particular from—

In some embodiments, M of the general formula 2a is a metal selected from the group of Fe, or, in particular M is or, more particularly M is Fe and wherein and are selected independently from any other and from—in particular from—or

-   -   wherein in particular is situated on the neighboring carbon atom         of the cp-ligand with respect to the attachment position of the         organometallic moiety (yielding a 1,2 substitution pattern on         the cp-ligand).

In some embodiments, M of the general formula 2a is a metal selected from the group of Fe, or Mn, in particular M is or, more particularly M is Fe, Y is C or N, and z of is 0, y of is 1 or 2, in particular z is 1, and wherein each is selected independently from any other from—, in particular from—

In some embodiments, M of the general formula 2a is a metal selected from the group of Fe, in particular M is Fe or, more particularly and z of is 0, and wherein is selected from or in particular from—wherein in particular R^(u) is situated on the neighboring carbon atom of the cp-ligand with respect to the attachment position of the organometallic moiety (yielding a 1,2 substitution pattern on the cp-ligand).

In some embodiments, Y is z of is 0 and y of is 0. In some embodiments, Y is z of 0, y of is 0, and M of the general formula 2a is selected from the group of or Co, in particular M is Fe or Ru, more particularly M is Fe.

In some embodiments, Y is C, z of is 0 and y of is 0. In some embodiments, Y is C, and M of the general formula 2a is selected from the group of in particular, more particularly M is Fe.

In some embodiments, and M of the general formula 2a is selected from the group of particular M is or more particularly M is Fe.

In some embodiments, i of and M of the general formula 2a is selected from the group of or in particular M is Fe or Ru, more particularly M is Fe.

In some embodiments, Y and M of the general formula 2a is selected from the group of or Mn, in particular, more particularly M is Fe.

In some embodiments, M of the general formula 2a is selected from the group of or in particular M is selected from or more particularly M is Fe or

-   -   —C(═S), with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl.

In some embodiments, M of the general formula 2a is selected from the group of in particular M is selected from more particularly is 0, i of and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   with l being 1, q of K_(q) is 0, K_(p) is C₁-alkyl;     -   with l being 1, q of K_(q) is 0, K_(p) is C₂-alkyl;     -   F_(l) is with l being 1, q of is 0, is C₁-alkyl,     -   with l being 1, q of is 0, is-alkyl,

wherein is selected from—in particular from—wherein in particular—, more particularly—, are situated on the neighboring carbon atom of the op-ligand with respect to the attachment position of the organometallic moiety (yielding a 1,2 substitution pattern on the cp-ligand).

In some embodiments, M of the general formula 2a is Y is C, z of is 0, y of is 0, i of, r of and t of are 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   or —C(═S), with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, q of is 0, is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl

In some embodiments, M of the general formula 2a is and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   with l being 1, q of K_(q) is 0, K_(p) is C₁-alkyl;     -   with l being 1, q of K_(q) is 0, K_(p) is C₂-alkyl;         wherein is selected from—, in particular from—     -   wherein more particularly—in particular from—or are situated on         the neighboring carbon atom of the cp-ligand with respect to the         attachment position of the organometallic moiety (yielding a 1,2         substitution pattern on the cp-ligand)

In some embodiments, M of the general formula 2a is selected from the group of or Mn, in particular M is selected, more particularly M is or is 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl.

In some embodiments, M of the general formula 2a is selected from the group, of or Mn, in particular M is selected from, more particularly is 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl,     -   l being 1, q of is 0, is -alkyl.         wherein R^(u) is selected from or, in particular from     -   or wherein more particularly—or—in particular from—or, are         situated on the neighboring carbon atom of the cp-ligand with         respect to the attachment position of the organometailic moiety         (yielding a 1,2 substitution pattern on the cp-ligand).

In some embodiments, M of the general formula 2a is s 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is —or -alkyl;     -   with l being 1, q of is 0,is C₁— or -alkyl;     -   with l being 1, p of is 0,is C₁— or C₂ -alkyl;     -   with l being 1, p of is—or C₂-alkyl, is—or -alkyl;     -   with l being 1, q of is 0,is C₁-alkyl;     -   with l being 1, q of is 0,is -alkyl;     -   with l being 1, q of is 0,is C₁— or -alkyl;     -   with l being 1, q of is 0,is C₂-alkyl;

In some embodiments, M of the general formula 2a is Fe, Y is and

-   -   with l being 1, q of is 0, p of is     -   with l being 1, q of is 0, p of     -   with l being 1, q of is 0,is -alkyl;     -   with l being 1, q of is 0,is -alkyl;     -   with l being 1, p of is 0,is -alkyl;     -   with l being 1, p of is -alkyl, -alkyl;     -   with l being 1, q of is 0,is alkyl;     -   with l being 1, q of is 0,is -alkyl;     -   with l being 1, q of is 0,is alkyl; or     -   with l being 1, q of is 0,is -alkyl;         wherein is selected from in particular from         wherein more particularly—, in particular from are situated on         the neighboring carbon atom of the cp-ligand with respect to the         attachment position of the organometallic moiety (yielding a 1,2         substitution pattern on the cp-ligand).

The metal sandwich complex of the general formula (2a) in the above mentioned embodiments may be neutral or cationic species, particularly the metal sandwich complex with M being Co may be in the cationic form comprising a counter anion selected from

In some embodiments, OM is a half metal sandwich complex of the general formula (2b),

wherein M is a metal selected from the group of Mn, Re or Tc, and

-   -   z of is 0, 1, 2, 3 or 4, and     -   each is independently from any other selected from         -   an unsubstituted or substituted alkyl an unsubstituted or             substituted alkenyl, an unsubstituted or substituted             alkynyl, an unsubstituted or cycloalkyl, an unsubstituted or             substituted alkoxy an unsubstituted or substituted             cycloalkoxy,         -   an unsubstituted or substituted aryl,         -   an unsubstituted or substituted 5- to 10-membered             heteroaryl, wherein 1 to 4 ring atoms are independently             selected from nitrogen, oxygen or sulfur,         -   an unsubstituted or substituted 5- to 10-membered             heteroalicyclic ring, wherein 1 to 3 ring atoms are             independently nitrogen, oxygen or sulfur,         -   wherein             -   are independently selected from the group consisting of                 hydrogen, unsubstituted or substituted alkyl, in                 particular a unsubstituted alkyl, and alkyl substituted                 with alkoxy.

In some embodiments, z of of the general formula 2b is 0, 1, 2, 3 or 4, and each is independently from any other selected from are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of of the general formula 2b is 1 and R^(u) is situated on the neighboring carbon atom of the cp-ligand with respect to the attachment position of the organometallic moiety (yielding a 1,2 substitution pattern on the cp-ligand),

In some embodiments, z of of the general formula 2b is 1, and is selected from—wherein and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of of the general formula 2b is 1, and is selected from wherein and are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of of the general formula 2b is 1, and is selected from, in particular from—are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, z of of the general formula 2b is 1 and is selected from—in particular from—, wherein in particular R^(u) is situated on the neighboring carbon atom of the cp-ligand with respect to the attachment position of the organometallic moiety (yielding a 1,2 substitution pattern on the cp-ligand),

In some embodiments, z of of the general formula 2b is

In some embodiments, M of the general formula 2b is and t of are 0, and

-   -   or with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0,-alkyl;     -   with l being 1, q of is 0,-alkyl;     -   with l being 1, p of is 0,-alkyl;     -   with l being 1, p of is —or -alkyl, is —or -alkyl;     -   with l being 1, q of is 0,is alkyl;     -   with l being 1, q of is 0,-alkyl;     -   with l being 1, q of is 0,alkyl;     -   with l being 1, q of is 0,is -alkyl;

In some embodiments, M of the general formula 2b is and t of K_(t) are 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   F_(l) is —with l being 1, q of is 0, p of is 0;     -   F_(l) is ——C(═S), with l being 1, q of is 0, is —or —alkyl;     -   F_(l) is with l being 1, q of is 0, is —or -alkyl;     -   F_(l) is with l being 1, p of is 0, is C₁—or -alkyl;     -   with l being 1, p of -alkyl, is -alkyl;     -   with l being 1, q of is alkyl;     -   with l being 1, q of is alkyl,     -   with l being 1, q of is -alkyl;         wherein in particular is selected from, in particular from         or—wherein more particularly in particular from—, are situated         on the neighboring carbon atom of the cp-ligand with respect to         the attachment position of the organometailic moiety (yielding a         1,2 substitution pattern on the cp-ligand).

In some embodiments, M of the general formula 2b is is 0, and

-   -   with l being 1, q of is 0, p of is 0;     -   with l being 1, q of is 0, p of is 0;     -   with l being -alkyl;     -   is with l being 1, q of -alkyl;     -   is with l being 1, p of -alkyl;     -   is with l being 1, p of -alkyl, is or -alkyl;     -   is —with l being 1, q of is 0, is C₁-alkyl;     -   l being 1, q of is 0, is -alkyl     -   l being 1, q of is 0, -alkyl,     -   l being 1, q of is 0, -alkyl,

In some embodiments, M of the general formula 2b is or of is 1, and

-   -   is —or —with l being 1, q of is 0, p of is     -   is with l being 1, q of is 0, p of is     -   or —with l being 1, q of is is —or -alkyl;     -   is with l being q of is is —or -alkyl;     -   is with l being p of is 0, is —or -alkyl;     -   is with l being 1, p of or -alkyl, is —or -alkyl;     -   is with l being 1, q of K_(q) is 0, is -alkyl;     -   is with l being 1, q of K_(q) is 0, is -alkyl;     -   is with l being 1, q of is is -alkyl;

Wherein in particular is selected from —in particular from or, wherein more particularly —, in particular from or are situated on the neighboring carbon atom of the cp-ligand with respect to the attachment position of the organometailic moiety (yielding a 1,2 substitution pattern on the cp-ligand).

The half metal sandwich complex of the general formula (2b) in the above mentioned embodiments may be neutral or cationic species, particularly the half metal sandwich complex with M being Co may be in the cationic form comprising a counter anion CA selected from

In some embodiments, OM is a metal sandwich complex of the general formula (2c),

-   -   wherein R^(c) is selected from     -   hydrogen,     -   an unsubstituted or substituted alkyl an unsubstituted or         substituted alkenyl, an unsubstituted or substituted alkynyl, an         unsubstituted or substituted cycloalkyl, an unsubstituted or         substituted alkoxy an unsubstituted or substituted cycloalkoxy,     -   an unsubstituted or substituted aryl,     -   an unsubstituted or substituted 5- to 10-membered heteroaryl,         wherein 1 to 4 ring atoms are independently selected from         nitrogen, oxygen or sulfur,     -   an unsubstituted or substituted 5- to 10-membered         heteroalicyclic ring, wherein 1 to 3 ring atoms are         independently nitrogen, oxygen or sulfur,

wherein

and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, in particular a alkyl, and alkyl substituted with alkoxy.

In some embodiments, of the general formula 2c is selected from, wherein and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy. In some embodiments, of the general formula 2c is selected from—wherein and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy. In some embodiments, of the general formula 2c is selected from —wherein R³ and are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, and alkyl substituted with alkoxy.

In some embodiments, of the general formula 2c is hydrogen.

In some embodiments, of the general formula 2c is an unsubstituted or substituted alkyl. in particular an unsubstituted alkyl, an unsubstituted or substituted alkenyl, an unsubstituted or substituted alkynyl, an unsubstituted or substituted cycloalkyl, an unsubstituted or substituted alkoxy, an unsubstituted or substituted cycloalkoxy.

Particular embodiments of this aspect of the invention are:

-   -   a. N-(1(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide (1)

-   -   b. 2-Ferroceneamido-2-2cyanopropyl ferrocenate (2)

-   -   c. 2-Ferroceneamido-2-2cyanopropyl ferrocenate (2a)

The compounds of the general formula (1) can also be obtained in the form of their hydrates and/or also can include other solvents used for example for the crystallization of compounds present in the solid form. Depending on the method and/or the reaction conditions, compounds of the general formula (1) can be obtained in the free form or in the form of salts.

The compounds of the general formula (1) may be present as optical isomers or as mixtures thereof The stereocenter is marked with an asterisk in the general formulas and is located on the C1 carbon atom of the ethyl moiety, however, the stereocenter is not depicted in all of the formulas of the specific compounds due to simplicity reasons. The invention relates both to the pure isomers, racemic mixtures and ail possible isomeric mixtures and is hereinafter understood as doing so, even if stereochemical details are not specifically mentioned in every case. Enantiomeric mixtures of compounds of the general formula (1), which are obtainable by the process or any other way, may be separated in known manner—on the basis of the physical-chemical differences of their components—into pure enantiomers, for example by fractional crystallisation, distillation and/or chromatography, in particular by preparative HPLC using a chiral HPLC column.

According to the invention, apart from separation of corresponding isomer mixtures, generally known methods of diastereoselective or enantioselective synthesis can also be applied to obtain pure diastereoisomers or enantiomers, e.g. by carrying out the method described hereinafter and using educts with correspondingly suitable stereochemistry.

It is advantageous to isolate or synthesize the biologically more active isomer, provided that the individual compounds have different biological activities,

A further object of the invention is the process for the preparation of the compounds described by the general formula (1).

The preparation comprises a compound described by the following general formula

Compound 3 comprising the substituents and M as defined above, is a known compound, which can be purchased or may be synthesized by known procedures or may be prepared analogously to known compounds. Such procedures are described by, without being limited to it, Patra et. al. (J, Med. Chem. 2012, 55, 8790-8798; Apreutesel et al. (Appl. Organomet. Chem. 2005, 19, 1022-1037), Bonini et al. (Eur. J. Org, Chem. 2002, 543-550); Routaboul et al. (J. Organomet, Chem., 2001, 637, 364-371), Q is a leaving group or OH, in particular Q is a leaving group as described in WO2005/044784 A1. Optionally, a group Z of the general formula —K_(r)—F_(l)—K_(t)— (with the meaning as defined above and as depicted in the genera) formula 1) may be introduced between then moiety and the organometallic OM of compound 2.

In some embodiments, compound 3′ is used instead of compound 3.

The reaction pathway is the same as described in Scheme 1 and 2. Compound 3′ is producible according to Rhode et. al. ((and references therein)). M, Q and Y have the same meaning as defined above. Optionally, before compound 2′ is used the moiety may be converted to a moiety via an oxidation according to Trudell et al. Optionally, a group Z of the general formula (with the meaning as defined above and as depicted in the general formula 1) may be introduced between then moiety and the organometallic OM of compound 2′.

The preparation comprises further a compound described by the following general formula

Compound 4 comprises the substituents as defined above. W is O or S. In some embodiments, W is O and Q is Cl and the reaction takes place in the presence of NEt₃ in some embodiments, W is O and Q is OH and the reaction takes place in the presence of HATU (O-(7-azabenzotriazol-1-yl)-tetramethyluronium-hexafluorophosphate), DIPEA (N,N-Diisopropylethylamine) dimethylformamid (comparable to the procedure of Patra et al. Optionally, an alkyl group K_(q) (with the meaning as defined above) may be introduced between the —C═W moiety (with W being O or S) and the group Q. Compound 4 is a known compound, which can be purchased or may be synthesized by known procedures or may be prepared analogously to known compounds. Such procedures are described for example by Patra et al.), Apreutesei et al. (Appl. Organomet Chem. 2005, 19, 1022-1037), Bonini et al. Routaboul et al.

The preparation comprises further a compound described by the following general formula

Compound 5 comprises the substituents as defined above. Compound 5 (see scheme 1) is formed by a reaction of the organometailic moiety OM of the formula 2a according to a synthetic method similar to the method employed by Gasser

Scheme 1: Formation of compound 5 from compound 5′ according to a synthetic method similar to the method employed by Gasser at al. (J. Organomet Chem. 2007, 692., 3835-3840). Compound 5′ comprising the substituents p of K_(p) as defined above, is a known compound, which can be purchased or may be synthesized by known procedures or may be prepared analogously to known compounds. Such procedures are described by, without being limited to it, Patra et al.

In one embodiment, compound 3 was treated with compound 6 in the presence of Triethylamine yielding compound 7. The reaction pathway is depicted in scheme 2.

Scheme 2: The 2-amino-2-hydroxymethylproprionitrile derivative 4 was produced according to an adapted procedure according to and Q of compound 3 and 7 have the same meaning as defined above. Compound 3 was reacted with one equivalent of compound 6 yielding compound 7 according to an adapted procedure from Gasser et al. (J. Organomet. Chem. 2010, 695, 249-255). In some embodiments, is and the reaction takes place in the presence of NEt₃. In some embodiments, is and the reaction takes place in the presence of HATU, DIPEA in N,N-dimethylformamid (comparable to the procedure of Patra et al. (Organometallics, 2010, 29, 4312-4319)). In some embodiments, the group may be exchanged to the leaving group Cl according to a procedure described by Lorkowsksi et. al. (VIII. Preparation of monomeric and polymeric ferrocenylene oxadiazoles, J. Prakt. Chem. 1967, 35, 149-58), by Witte et al.

-   -   or by Cormode et al. (Dalton Trans. 2010, 39, 6532-6541═.

In one embodiment, compound 4 was reacted with compound 7, according to an adapted procedure of Gasser yielding compound 8a. The reaction pathway is depleted in scheme 3.

Scheme 3: Compound 4 was reacted with compound 7, according to an adapted procedure of Gasser et al. yielding compound 8a. and p of have the meaning as defined above. In some embodiments, W is O and Q is Cl and the reaction takes place in the presence of In some embodiments, W is O and Q is OH and the reaction takes place in the presence of HATU, DIPEA in N,N-dimethylformamid (comparable to the procedure of Patra et al. Optionally, an alkyl group (with the meaning as defined above) may be introduced between then —C═W moiety (with W being O or S) and the group Q. Optionally, a group Z of the general formula (with the meaning as defined above and as depicted in the general formula 1) may be introduced between then moiety and the organometallic OM of compound 2

In one embodiment, compound 5 was treated with compound 7, according to an adapted procedure of Gasser et al. (J. Organomet Chem., 2007, 692, 3835-3840), yielding compound 8b. The reaction pathway is depicted in scheme 4.

Scheme 4: Compound 5 was reacted with compound 7, according to an adapted procedure of Gasser et al. and Gasser et al. (J. Med. Chem. 2012, 55, 8790-8798). and p of have the same meaning as defined above.

In one embodiment, two equivalents of compound 3 were reacted with one equivalent of compound 6 yielding compound 9. The reaction pathway is depicted in scheme 5.

Scheme 5: Two equivalents of compound 3 were reacted with one equivalent of compound 6, according to an adapted procedure from Gasser et al. (J. Organomet Chem. 2010, 695, 249-255), yielding compound, and M have the meaning as defined above. In some embodiments Q is a halide, a mesylate or a tosylate. In some embodiments, G is Cl and the reaction takes place in the presence of NEt₃. In some embodiments, Q is OH and the reaction takes place in the presence of HATU, DIPEA in N, N-dimethylformamid (comparable to the procedure of Patra et al. (Organometallics, or Gasser et al.

Reaction pathways for compounds comprising the half metal sandwich complexes OM of the general formula 2b follow a similar pathway as the above mentioned reactions, in particular a similar pathway as depicted in scheme 2 to scheme 4, which are easily adaptable for a person skilled in the art. Reference is made to the above cited conditions, references and reactions pathways.

Metal sandwich complex of the general formula (2a) and half metal sandwich complex of the general formula (2b) follow a similar pathway as the above mentioned reactions depicted in scheme 1 and scheme 2, which are easily adaptable for a person skilled in the art. In particular an adaption may be based on publication of Wolter-Steingrube et al. (“Synthesis and Molecular Structures of Monosubstituted Pentamethylcobaltocenium Cations”, Eur. J. Inorg. Chemsee also Vanicek et al., Organometallics, dx.doi,org/10.1021/om401120h E, Fourie et al., Journal of Organometallic Chemistry

A reaction pathway for compounds comprising carbonyl complexes OM of the general formula 2c is depicted in scheme 6.

Scheme 6: Compound 6 was reacted with compound 10 in the presence of HATU and DIEPA, yielding compound 11 (see Patra et al., X is a group described by a general formula as defined above. Furthermore, have the same meaning as defined above. Compound 11 is then reacted with compound 12 according to an adapted procedure of Gauvry et al., yielding compound 13. Subsequently compound 13 is then reacted with 2 equivalents according to an adapted synthetic method employed by Gasser et al. yielding compound 14. Optionally, a group Z of the general formula (with the meaning as defined above and as depicted in the general formula 1) may be introduced between the moiety and the alkyne moiety of compound 10. Compound 10 and 12 are known compounds, which can be purchased or may be synthesized by known procedures or may be prepared analogously to known compounds (see for example Zeinyeh et al.

According to a third aspect of the invention, the compounds defined as the first aspect of the invention are provided for use in a method for treatment of disease.

Pharmaceutical acceptable sate of the compounds provided herein are deemed to be encompassed by the scope of the present invention. According to one aspect of the invention, a pharmaceutical composition for preventing or treating helminth infection, particularly infection by tapeworms (cestodes), flukes (trematodes) and roundworms (nematodes), in particular species of Haemonchus, Trichstrongylus, Teladorsagia, Cooperia, Oesophagostomum and/or Chabertia, tapeworm infection, schistosomiasis, ascariasis, dracunculiasis, elephantiasis, enterobiasis, filariasis, hookworm infection, onchocerciasis, trichinosis and/or trichuriasis is provided, comprising a compound according to the above aspect or embodiments of the invention.

Pharmaceutical compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as dermal (spot-on), intradermal, subcutaneous, intravenous, intrahepatic or intramuscular administration, may be used. The pharmaceutical compositions comprise approximately 1 % to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.

According to one aspect of the invention, a dosage form for preventing or treating helminth infection, particularly infection by particularly tapeworms (cestodes), flukes (trematodes) and roundworms (nematodes), tapeworm infection, schistosomiasis, ascariasis, dracunculiasis, elephantiasis, enterobiasis, filariasis, hookworm infection, onchocerciasis, trichinosis and/or trichuriasis is provided, comprising a compound according to the above aspect or embodiments of the invention. Dosage forms may be for administration via various routes, including nasal, buccal, rectal, transdermal or oral administration, or as an inhalation formulation or suppository. Alternatively, dosage forms may be for parenteral administration, such as intravenous, intrahepatic, or especially subcutaneous, or intramuscular injection forms. Optionally, a pharmaceutically acceptable carrier and/or excipient may be present.

According to one aspect of the invention, a method for manufacture of a medicament for preventing or treating helminth infection, particularly infection by particularly tapeworms (cestodes), flukes (trematodes) and roundworms (nematodes), tapeworm infection, schistosomiasis, ascariasis, dracunculiasis, elephantiasis, enterobiasis, filariasis, hookworm infection, onchocerciasis, trichinosis and/or trichuriasisis provided, comprising the use of a compound according to the above aspect or embodiments of the invention. Medicaments according to the invention are manufactured by methods known in the art, especially by conventional mixing, coating, granulating, dissolving or lyophilizing.

According to one aspect of the invention, a method for preventing or treating helminth infection, particularly the indications mentioned previously, is provided, comprising the administration of a compound according to the above aspects or embodiments of the invention to a patient in need thereof.

The treatment may be for prophylactic or therapeutic purposes. For administration, a compound according to the above aspect of the invention is preferably provided in the form of a pharmaceutical preparation comprising the compound in chemically pure form and optionally a pharmaceutically acceptable carrier and optionally adjuvants. The compound is used in an amount effective against helminth infection. The dosage of the compound depends upon the species, the patient age, weight, and individual condition, the individual pharmacokinetic data, mode of administration, and whether the administration is for prophylactic or therapeutic purposes. The daily dose administered ranges from approximately 1 μg kg to approximately 1000 mg/kg, preferably from approximately 1 μg to approximately 100 μg, of the active agent according to the invention. Wherever reference is made herein to an embodiment of the invention, and such embodiment only refers to one feature of the invention, it is intended that such embodiment may be combined with any other embodiment referring to a different feature. For example, every embodiment that defines OM may be combined with every embodiment that defines or to characterize a group of compounds of the invention or a single compound of the invention with different properties.

The invention is further characterized, without limitations, by the following examples and figure, from with further features, advantages or embodiments can be derived. The examples and figures do not limit but illustrate the invention.

SHORT DESCRIPTION OF THE FIGURES

FIG. 1 shows a spectrum of Compound 1 in d₆-acetonitrile at room temperature;

FIG. 2 shows a NMR spectrum of Compound 2 in d₆-Acetone at room temperature.

FIG. 3 shows the effect of compound 1 on a elegans worm suspension (the number of dead or immobile worms after an incubation of 24 h is displayed);

FIG. 4 shows the effect of compound 2 on a C. elegans worm suspension (the number of dead or immobile worms after an incubation of 24 h is displayed).

GENERAL METHODS Materials

All chemicals were of reagent grade quality or better, obtained from commercial suppliers and used without further purification. Solvents were used as received or dried over 4A and 3A molecular sieves. and were freshly distilled under N₂ by employing standard procedures. All syntheses were carried out using standard Schlenk techniques.

Instrumentation and Methods: and—NMR spectra were recorded in deuterated solvents on a Bruker DRX 400 or AV2 500 at 30° C. The chemical shifts δ, are reported in ppm. The residual solvent peaks have been used as internal reference. The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Infrared spectra were recorded on a PerkinElmer spectrum BX TF-IR spectrometer and KBr presslings were used for solids. Signal intensities are abbreviated w (weak), m (medium), s (strong) and br (broad). ESI mass spectra were recorded on a Bruker Esquire 6000 or on a Bruker maxis QTOF-MS instrument (Bruker Daltonics GmbH, Bremen, Germany). The LC-MS spectra were measured on an Acquity™ from Waters system equipped with a PDA detector and an auto sampler using an Agilent Zorbax 300SB-C18 analytical column (5.0 μm particle size, 100 Å pore size, 150×3.0 mm) or an Macherey—Nagel 100 —5 C18 (3.5 μm particle size, 300 Å pore size, 150×3.0 mm). This LC was coupled to an Esquire HCT from Bruker (Bremen, Germany) for the MS measurements. The LC run (flow rate: 0.3 mL min-1 ) was performed with a linear gradient of A (distilled water containing 0.1% v/v formic acid) and B (acetonitrile (Sigma-Aldrich HPLC-grade), t=0 min, 5% B; t=3 min, 5% B; t=17 min, 100% B; t=20 min, 100% B; t=25 min, 5% B. High-resolution ESI mass spectra were recorded on a Bruker maxis QTOF-MS instrument (Bruker Daltonics GmbH, Bremen, Germany). The samples (around 0.5 mg) were dissolved in 0.5 mL of 1:1+0.1%. The solution was then diluted 10:1 and analysed via continuous flow injection at 3 μl min⁻¹. The mass spectrometer was operated in the positive electrospray ionization mode at 4000 V capillary voltage, −500 V endplate offset, with a N₂ nebulizer pressure of 0.4 bar and dry gas flow of 4.0 l/min at 180° C. MS acquisitions were performed in the full scan mode in the mass range from m/z 100 to 2000 at 20,000 resolution and 1 scan per second. Masses were calibrated with a 2 mmol/l solution of sodium formate over m/z 158 to 1450 mass range with an accuracy below 2 ppm.

Cell Culture:

Human cervical carcinoma cells (HeLa) were cultured in DMEM (Gibco) supplemented with 5% fetal calf serum (FCS, Gibco), 100 U/ml penicillin, streptomycin at 37° C. and 5% CO₂. The normal human fetal lung fibroblast MRC-5 cell line was maintained in F-10 medium (Gibco) supplemented with 10% FCS (Gibco), 200 mmol/l L-Glutamine, 100 U/ml penicillin, and streptomycin at 37° C. and 5% C02. To establish the anticancer potential of the compounds they were tested in one cell line, namely HeLa by a fluorometric cell viability assay using Resazurin (Promocell GmbH). Compounds showing cytotoxicity were then tested on normal MRC-5 cells. 1 day before treatment, cells were plated in triplicates in 96-well plates at a density of cells/well in for HeLa and 7×10³ cells/well for MRC-5 cells. Cells were treated with increasing concentrations of the compounds for 2 days. After 2 days, medium and drug were removed and 100 ml fresh medium containing Resazurin (0.2 mg/ml final concentration) were added. After 4 h of incubation at 37° C., the highly red fluorescent dye resorufin's fluorescence was quantified at 590 nm emission with 540 nm excitation wavelength in the SpectraMax M5 microplate Reader.

C. Elegans Movement Inhibition Assay:

Asynchronous N2 C. elegans worms (Bristol) were maintained on nematode growth medium (NGM) agar, seeded with a lawn on OP50 E coli as a food-source, according to standard protocol (Maintenance of C. elegans; Stiernagle, T., Ed.; WormBook, 2006.). Worms were harvested from NGM plates by washing with M9 buffer and aspiration and collection in a 10 mL tube (Falcon). The average number of worms in 5 μL of this suspension was calculated by transferring 4×5 μL aliquots to a glass slide (Menzel Glaser), and worms were enumerated under a compound microscope (Olympus CH30). To adjust the suspension to contain 1 worm per μL, M9 buffer was either added or removed after pelleting worms at 600 xg for 30 sec.

Dilution of Test Compounds, Zolvix (Monepantel) and DMSO for Working Stock Solutions and 96 Well Plate Set-Up for Liquid Screen:

A volume of M9 buffer was added to each well in a 96-well plate, using a multichannel pipettor, with a trimmed pipette tip (increased aperture to minimize damage to worms). The worm suspension was resuspended by flicking after every three wells to maintain consistency. The compounds were stored at 4° C., and diluted in dimethyl sulfoxide (DMSO) to achieve a concentration 1 hr prior to addition to assay. These stock solutions were diluted further in DMSO to create a series of and 0.002 mmol/l which were subsequently diluted 1 :20 in M9 buffer to create 10 μL of each concentration was added to wells in duplicate to achieve final concentrations of 100 μmol/l, 10 μmol/l, 100 nmol/l and 10 nmol/l in (0.5% DMSO). A Zolvix (monepantel) dilution series was simultaneously created following the same dilution schema, and used as a positive control; of 10 % DMSO was added to achieve 1 % DMSO vehicle control. 10 μL M9 was added to negative control wells (see FIG. 1). Plates were incubated at room temperature overnight at 20° C.

Quantitative Worm Mobility Scoring:

Immobile worms were counted as a percentage of total worms in each well using an Olympus SZ30 dissecting microscope. The immobile fraction was subtracted from the total, and this remainder was divided by the total to give a percentage of live worms per well. Descriptive and inferential statistics were deferred until further replicates are performed.

In vitro experiments can be conducted by testing compounds in a larval development assay. To do this, sheep are infected with infective third-stage larvae (L3) of species of Haemonchus, Trichstrongylus, Teladorsagia, Cooperia, Oesophagostomum or Chabertia. Faeces from these sheep are collected and used for experiments; ˜100 g of faeces are crushed homogenized and suspended in ˜1000 ml of sugar solution (specific gravity 1.2), put through a ‘tea strainer’ sieve, and the large undigested food material in the sieve discarded. The sugar solution is then placed into a flat dish and strips of plastic overhead transparency film placed on the surface. The plastic is left for at least 45 minutes to allow the eggs to stick and then removed carefully. The eggs are collected by washing them from the plastic film, with water, into a 50 ml centrifuge tube. The water containing egg suspension eggs is put through a 40 mm sieve to remove further plant material and then centrifuged at 1 ,000 xg for 10 minutes. The supernatant is checked for eggs and then discarded as the majority of eggs are at the bottom of the tube. These eggs are collected in 1 ml of water and diluted to ˜200 eggs/20 ml.

1. Each compound is tested at five concentrations: 100, 50, 25, 12.5 and 6.25 mmol/l (i.e. serial 2-fold dilutions starting from 100 mmol/l). Dilutions of each compound (10 ml in total) are performed in 1.5 ml microcentrifuge tubes, 1 ml of molten agar added, the tube vortexed and the agar aliquoted (150 ml) into the wells of a 96-well microtitre plate.

2. DMSO is used in a number of wells as solvent-only controls (negative controls) whilst cydectinis used as a positive control. Concentrations of cydectin used for positive controls for the compound re-testing are: 6.25, 12.5, 25, 50 and 100 mmol/l.

3. -100 eggs (20 ml) are then added to each well.

4. Plates are then incubated overnight at 27° C.

5. Plates are checked the following morning and afternoon to ensure that most eggs had hatched. Any compounds that appeared to have an ovicidal effect are noted.

6. Following hatching of most eggs, 15 ml of nutritive medium is added to feed the larvae. Nutritive medium is prepared as follows: 1 g of yeast extract is added to 90 ml of 0.85% physiological saline and autoclaved for 20 mins at 121° C. Three millilitres of 10 x Earle's balanced salt solution is added to 27 ml of yeast extract solution and the pH of the solution adjusted to 5.4-5.6 by the addition of bicarbonate.

7. Following 7 days additional incubation, the numbers of L3 larvae that had developed in each well is determined.

In vivo experiments can be conducted in sheep monospecifically infected with these parasites (i.e. species of Haemonchus, Trichstrongylus, Teladorsagia, Cooperia, Oesophagostomum or Chabertia)

ENDO PARASITES Activity in Vitro Against Dirofilaria Immitis (Di) (Filarial Nematodes).

Freshly harvested and cleaned microfilariae from blood from donor animals are used (dogs for Di).The microfilariae are then distributed in formatted microplates containing the test substances to be evaluated for antiparasitic activity. Each compound is tested by serial dilution in order to determine its minimum effective dose (MED). The plates are incubated for 48 hours at 26° C. and 60% relative humidity (RH). Motility of microfilariae is then recorded to identify possible nematocidal activity. Efficacy is expressed in percent reduced motility as compared to the control and standards.

Activity in Vitro Against Haemonchus contortus & Trichostrongylus colubriformis (Gastrointestinal Nematodes).

Freshly harvested and cleaned nematode eggs are used to seed a suitably formatted microplate containing the test substances to be evaluated for antiparasitic activity. Each compound is tested by serial dilution in order to determine its MED. The test compounds are diluted in nutritive medium allowing the full development of eggs through to 3rd instar larvae. The plates are incubated for 6 days at 28° C. and 60% relative humidity (RH). Egg-hatching and ensuing larval development are recorded to identify a possible nematocidal activity.

Efficacy is expressed in percent reduced egg hatch, reduced development of L3, or paralysis & death of larvae of all stages.

EXAMPLES OF SYNTHETIC PATHWAYS Example 1

Synthesis of compound 1 (N-(1-(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide)

The proposed synthetic pathway is depicted in Scheme 7.

Scheme 7: Reagents and conditions: (a) tert-butoxide, (b) CH₂Cl₂, oxalyl chloride, reflux→r.t., overnight; (c) overnight, 20%; (d) and 18-crown-6,

Compound 15 was reacted with tert-butoxide, t-BuLi and yielding compound 3a. The synthesis of ferrocenecarboxylic acid 3a (step a) was adapted from a procedure from Witte et al. (Organometallics 1999, 18, 4147). Compound 3a was reacted with oxalyl chloride under reflux yielding compound 3b. The synthesis of chlorocarbonyl ferrocene 3b (step b) was adapted from a procedure of Cormode et al. Optionally an adapted procedure of Lorkowski et. al. (VIII. Preparation of monomeric and polymeric ferrocenylene oxadiazoles, J. Prakt. Chem. 1967, 35, 149-58) may be applied. Chlorocarbonyl ferrocene 3b and 2-amino-2-hydroxymethylproprionitrile 6 were dissolved in dry THF and Triethylamine was added (step c). After evaporation of the solvent and purification by column chromatography N-(2-cyano-1-hydroxypropan-2-yl)ferroceneamide 7a was isolated in 29% yield according to an adapted procedure of Compound 7a was reacted with one equivalent of 5a in the presence of and 18-crown-6 in dry according to an adapted procedure of Gasser et al. (J. Organomet. Chem. 2007, 692, 3835-3840) and Gasser et al. (J. Med. Chem. 2012, 55, 8790-8798), yielding compound 1 in a yield of 43%.

Example 2

Synthesis compound 2 (Ferroceneamido-2-2cyanopropyl ferrocenate)

The proposed synthetic pathway is depicted in Scheme.8.

Scheme 8: Two equivalents of Chlorocarbonyl ferrocene 3b and one equivalent of 2-amino-2-hydroxymethylproprionitrile 6 were dissolved in dry THF and Triethylamine was added. After evaporation of the solvent and purification by column chromatography Ferroceneamido-2-2cyanopropyl ferrocenate 2 was isolated in: 29% yield. Syntheses and Characterization

Ferrocenecarboxylic Acid (3a):

The synthesis of ferrocenecarboxylic acid 3a was adapted from a procedure from Witte et al.

Ferrocene 15 and potassium tert-butoxide (0.46 g, 4.08 nmol) were completely dissolved in dry The orange solution was cooled to −78° C. when tert-butyllithium) was added dropwise over a period of 15 min, with the temperature maintained beiow −70 ° C. The reaction mixture was stirred at −78° C. for 1 h and then poured on a slurry of dry ice (excess) and diethyl ether. The mixture was warmed to room temperature overnight and extracted with an aqueous solution of sodium hydroxide The combined aqueous layers were neutralized with hydrochloric acid and the resulting orange solid was extracted with until the organic layer remained colourless. The combined organic layers were filtered to remove traces of ferrocenedicarboxylic acid, dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure to give ferrocenecarboxylic acid as an orange solid in 35% yield. The spectroscopic data of the product matched that reported previously by Witte et al.

Chlorocarbonyl Ferrocene 3b;

The synthesis of chlorocarbonyl ferrocene 3b was adapted from a procedure of Cormode et al. (Dalton Trans. 2010, 39, 6532), After suspending ferrocene-carboxylic acid 3b in dry oxalyl chloride in dry was added dropwise to the reaction mixture whereby the orange suspension turned dark red. The reaction mixture was refluxed for 2 h and then stirred overnight at room temperature. The solvent was then removed under vacuum. The product was not purified and used immediately for the next synthetic step.

2-Amino-2-Hydroxymethylproprionitrile 6:

2-Amino-2hydroxymethylproprionitrile 4 was prepared following the procedure published by

N-(2-cyano-1-hydroxypropan-2-yl)ferroceneamide 7a:

Chlorocarbonyl ferrocene and 2-amino-2-hydroxymethylproprionitrile were dissolved in dry THF (15 ml), Triethyiamine was added to the solution and the reaction mixture was stirred overnight at room temperature. The solvent was evaporated under reduced pressure and the crude product was purified by column chromatography on silica with hexane:ethyl acetate as the eluent The contaminated product was washed with dichloromethane to give N-(2-cyano-1-hydroxypropan-2-yl)ferroceneamide 7a as a pure orange solid. Yield: 29%., found

(Ferrocenylmethyl)trimethylammonium iodide 5a

(Ferrocenyimethyi)trimethylammonium iodide 5a was prepared according to Lindsay et al (J. Org. Chem, 1957, 22, 355-358).

N-(1-(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide 1:

N-(2-cyano-1-hydroxypropan-2-yl)ferroceneamide (ferrocenylmethyl) trimethylammonium iodide 5a and 18-crown-6 (5.0 mg, 0.0192 mmol) were dissolved in dry and refluxed for 72 h. Then the reaction mixture was allowed to cool to room temperature. The solvent was evaporated under reduced pressure. Then the residue was redissolved in and washed with and brine The organic phase was dried over filtered and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on ssilica with hexane:ethyl acetate as the eluent to afford N-(1-(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide 1 as a yellow solid. Yield:, found

2-Ferroceneamido-2-2cyanopropyl ferrocenate 2:

Chlorocarfaonyl ferrocene and 2-amino-2-hydroxymethylproprionitrile were dissolved in dry THF Triethyiamine was added to the solution and the reaction mixture was stirred overnight at room temperature. The solvent was evaporated under reduced pressure and the crude product was purified by column chromatography on silica with hexane:ethyl acetate as the eluent to give 2-Ferroceneamido-2-2cyanopropyl ferrocenate 2 as a pure orange solid. Yield: Acetonecald for found

N-(2-cyano-1-hydroxypropan-2-yl)ruthenoceneamide (20a) and 2-Cyano-2-(ruthenocenecarboxamido)propyl ruthenocnecarboxylate (2a)

Chlorcarbonyl ruthenocene and 2-amino-2-hydroxymethyl proprionitrlie were dissolved in dry THF (50 mL) and NEt3 was slowly added and the mixture was stirred at room temperature for 16 h. The solvent was removed in vacuo and the yellow residue was purified by column chromatography on silica. First, N-(2-cyano-1 -hydroxypropan-2-yl)ruthenocenamide 20b was eluted with ethyl acetate:hexane (Rf=0.05 in 1 :7 ethyl acetate:hexane) and afterwards 2-cyano-2-(ruthenocenecarboxamido)propyl ruthenocnecarboxylate 2b was eluted with methanol as eluent (Rf=0.2 in methanol) from the same column, both as pale yellow solids. 20a was dissolved in boiling acetonitrile and recrystallized at −4° C. for 4 days. Yield=31%, 20b and 19%, 2a.

N-(2-cyano-1-hydroxypropan-2-yl)ruthenoceneamide Elemental Analysis: calcd. for 2-Cyano-2-(ruthenocenecarboxamido)propyl ruthenocnecarboxylate

Elemental Analysis: calcd. for

Cytotoxicity and Nematocidal Studies:

The toxicity towards human cervical cancer HeLa was investigated using the fluorometric cell viability For compounds which were found to be toxic towards HeLa cells, their cytotoxicity towards the human lung fibroblasts MRC-5 was also tested (see table 1 ).

C. elegans is widely used as a tool in the pharmaceutical and biotechnology industry to test the efficacy of compounds against nematodes and other organisms (cf. Divergence, Inc.—now aquired from the Montsanto Company), which has the major advantage that the modes/mechanisms of action and associated phenotypes can be fully characterised as well as resistance development assessed. Given that C. elegans and socioeconomic strongylid nematodes belong to clade V of the phylum Nematoda (Blaxter et al., 1998 Nature), there is a high likelihood that drug action will be effective/effected in strongylid nematodes.

TABLE 1 shows the toxicity towards human cervical cancer HeLa and towards the human lung fibroblasts MRC-5 using the fluorometric cell viability assay. Compound Compound 2 Compound 2a

Furthermore, the effect of compound 1 on a C. elegans worm suspension is depicted in FIG. 2. The number of dead or immobile worms after an incubation of 24 h is displayed. Table 2 comprises information concerning the effect of compound 1 on C. elegans and H. contortus. Interestingly, it was demonstrated that the mobility of the C. elegans worms was reduced at a concentration of 50 μM indicating a good nematocidal action of compounds 1 and 2.

Mobility in C. elegans Number of L3 at 50 μM/% H. contortus/100 μM Compound 1 Compound 2

The activity against Haemontus Contortus, Dirofilaria immitis and Trychostrongylus colubriformis was tested and the results are shown in table 3.

TABLE 3 shows the activity against Haemontus Contortus, Dirofilaria immitis and Trychostrongylus colubriformis Activity Activity Compound against against Activity against

0% 17%

—

—

As can be seen in Table 3, interesting EC values could be obtained, especially on compound 1 and 2a which had efficacies up to 54% at a dosage of Importantly, since racemic mixtures were used, it can be anticipated that higher activity will be obtain when pure enantiomers will be used. 

1. A compound characterized by a general formula (1),

wherein X is a group described by a general formula —K_(p)—F_(r)—K_(q)—, wherein F_(l) is —C(═O)—, —C(═S)—, with l being 0 or 1, K_(p) is a C_(p)-alkyl with p being 0, 1 , 2, 3 or 4, K_(q) is a C_(q)-alkyl with q being 0, 1 , 2, 3 or 4, and wherein each OM is an organometallic compound independently selected from each other from the group of an unsubstituted or substituted metal sandwich compound, an unsubstituted or substituted half metal sandwich compound or a metal carbonyl compound.
 2. The compound according to claim 1, wherein l of F_(l) is 0, q of K_(q) and p of K_(p) is 0 or l of F_(l) is 0, q of K_(q) is 0 and K_(p) is C₁-alkyl.
 3. The compound according to claim 1, wherein i of F_(i) is 0, r of K_(r) and t of K_(t) is
 0. 4. The compound according to claim 1, wherein at least one OM is an organometallic compound according to the general formula (2a),

wherein M is a metal selected from Fe, Ru, Co, Ni, Cr, Os or Mn, and Y is C or N, and z of R_(z) ^(U) is 0, 1 , 2, 3 or 4, and y of R_(y) ^(L) is 0, 1 , 2, 3, 4 or 5 and each R^(L) and each R^(U) are independently from any other R^(L) and R^(U) selected from an unsubstituted or substituted C₁-C₁₀ alkyl, in particular an unsubstituted C₁-C₄ alkyl an unsubstituted or substituted C₁-C₁₀ alkenyl, an unsubstituted or substituted C₁-C₁₀ alkynyl, an unsubstituted or substituted C₃-C₈ cycloalkyl, an unsubstituted or substituted C₁-C₁₀ alkoxy, an unsubstituted or substituted C₃-C₈ cycloalkoxy, an unsubstituted or substituted C₆-C₁₄, an unsubstituted or substituted 5- to 10-membered heteroaryl, wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring, wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, SCF₃, —SOCF₃ or —SO₂CF₃, or —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³ or —S(O)₂NR³R⁴, or —OCF₃, —CN, —CF₃, —SCN, F, Cl, Br or l, wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 5. The compound according to claim 4, wherein each R^(L) and each R^(U) are independently from any other R^(L) and R^(U) selected from —OCF₃, —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³ —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³, —S(O)₂NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, particularly from —OCF₃, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 6. The compound according to claim 4, wherein each R^(L) and each R^(U) are independently from any other R^(L) and each R^(U) selected from —SCF₃, —SOCF₃ or —SO₂CF₃.
 7. The compound according to claim 4, wherein M is selected from the group of Fe, Ru or Co, wherein in particular M is Fe or Ru, and wherein more particularly M is Fe.
 8. The compound according to claim 4, wherein Y is C.
 9. The compound according to claim 4, wherein y and z are
 0. 10. The compound according to claim 1, wherein at least one OM is an organometallic compound according to the general formula (2b),

wherein M is a metal selected from the group of Mn, Re or Tc, and z of R_(z) ^(U) is 0, 1, 2, 3 or 4, and each R^(u) is independently from any other R^(u) selected from an unsubstituted: or substituted C₁-C₁₀ alkyl an unsubstituted or substituted C₁-C₁₀ alkenyl, an unsubstituted or substituted C₁-C₁₀ alkynyl, an unsubstituted or substituted C_(e)-C₈ cycloalkyl, an unsubstituted or substituted C₁-C₁₀ alkoxy an unsubstituted or substituted C₃-C₈ cycloalkoxy, an unsubstituted or substituted C₆-C₁₄ aryl, an unsubstituted or substituted 5- to 10-membered heteroaryl, wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring, wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, SCF₃, —SOCF₃ or —SO₂CF₃, or —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³ or —S(O)₂NR³R⁴, or —OCF₃, —CN, —CF₃, —SCN, F, Cl, Br or l, wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 11. The compound according to claim 10, wherein each R^(U) is independently from any other R^(U) selected from —OCF₃, —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³ —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³, —S(O)₂NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, particularly from —OCF₃, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 12. The compound to claim 1, wherein at least one OM is an organometallic compound according to the general formula (2c),

wherein R^(c) is selected from hydrogen, an unsubstituted or substituted C₁-C₁₀ alkyl, in particular an unsubstituted or substituted C₁-C₄ alkyl an unsubstituted or substituted C₁-C₁₀ alkenyl, an unsubstituted or substituted C₁-C₁₀ alkynyl, an unsubstituted or substituted C₃-C₈ cycloalkyl, an unsubstituted or substituted C₃-C₈ cycloalkoxy, an unsubstituted or substituted C₁-C₁₀ alkoxy an unsubstituted or substituted C₃-C₈ cycloalkoxy, an unsubstituted or substituted C₆-C₁₄ aryl, an unsubstituted or substituted 5- to 10-membered heteroaryl, wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring, wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, SCF₃, —SOCF₃ or —SO₂CF₃, or —OCF₃, —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³ or —S(O)₂NR³R⁴, wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 13. The compound according to claim 12, wherein R^(c) is selected from —OCF₃, —OR³, —SR³, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³ —C(O)SR³, —C(O)NR³R⁴, —NR³R⁴, —S(O)₂R³, —S(O)₂OR³, —S(O)₂NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, particularly from —OCF₃, —C(O)R³, —C(S)R³ —C(O)OR³, —C(S)OR³, —C(O)SR³, —C(O)NR³R⁴, —SCF₃, —SOCF₃ or —SO₂CF₃, more particularly from —SCF₃, —SOCF₃ or —SO₂CF₃. wherein R³ and R⁴ are independently selected from the group consisting of hydrogen, unsubstituted or substituted C₁-C₄ alkyl, and C₁-C₄ alkyl substituted with C₁-C₄ alkoxy.
 14. The compound according to claim 1, wherein each of the two OM are selected independently from each other from compounds comprising the general formula 2a, 2b or 2c, wherein in particular both OM are selected from compounds of the general formula 2a or from compounds of the general formula 2b or from compounds of the general formula 2c.
 15. The compound according to claim 1, wherein both OM are the same.
 16. A compound according to claim 1 for use in a method of treatment of disease.
 17. A compound according to claim 1 for use in a method for treatment of infections by helminths, or for use in a method to suppress plant helminths. 